EXACT Therapeutics Announces Granted Patent in United Kingdom for Acoustic Cluster Therapy (ACT®)

OSLO, 30 May 2023: EXACT THERAPEUTICS AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announces that Intellectual Property Office in United Kingdom yesterday announced the issuance of UK Patent No. GB2595513 entitled “Treatment of infections”.

The granted patent claims cover EXACT-Tx’s unique microbubble/ microdroplet formulation (PS101) and its use, co-administered with a range of pharmaceutical agents for ultrasound mediated drug targeting for treatment of infections. This is an important step in securing EXACT-Tx’s mission to enhance the therapeutic outcome of the standard of care across drug classes for the benefit of patients across diseases.

For more information, please contact:

Per Walday

CEO EXACT Therapeutics

Email: per.walday@exact-tx.com

For the full press release: Press release